Skip to main content
main-content

01.12.2017 | Research | Ausgabe 1/2017 Open Access

Radiation Oncology 1/2017

Carbon-ion radiotherapy for non-small cell lung cancer with interstitial lung disease: a retrospective analysis

Zeitschrift:
Radiation Oncology > Ausgabe 1/2017
Autoren:
Mio Nakajima, Naoyoshi Yamamoto, Kazuhiko Hayashi, Masataka Karube, Daniel K Ebner, Wataru Takahashi, Makoto Anzai, Kenji Tsushima, Yuji Tada, Koichiro Tatsumi, Tadaaiki Miyamoto, Hiroshi Tsuji, Takehiko Fujisawa, Tadashi Kamada
Abbreviations
18F–FDG
[18F]-fluorodeoxyglucose
AE
Acute exacerbation
CIRT
Carbon-ion radiotherapy
CT
Computed tomography
CTCAE
Common Terminology Criteria for Adverse Events
HIMAC
Heavy Ion Medical Accelerator in Chiba
ILD
Interstitial lung disease
IPF
Interstitial pulmonary fibrosis
KL-6
Krebs von den Lungen-6
LC
Lung cancer
LCR
Local control rate
MRI
Magnetic resonance imaging
NIRS
National Institute of Radiological Sciences
NSCLC
Non-small cell lung cancer
OS
Overall survival
PET
Positron emission tomography
PTV
Planning target volume
RBE
Relative biological effectiveness
RP
Radiation pneumonitis
SBRT
Stereotactic body radiation therapy
SP-D
Surfactant protein-D

Background

Lung cancer (LC) is often associated with interstitial lung disease (ILD). The reported prevalence of LC in ILDs is 13–50%, particularly in the setting of interstitial pulmonary fibrosis (IPF) [14].
Treatment protocols for ILD-associated LC have not been well-established, as surgery, chemotherapy, and radiotherapy can all cause acute exacerbation (AE) of ILD. The postoperative AE frequency has been reported to be 9–25%; with a mortality rate of 11–86%, it accounts for the majority of treatment-related deaths [59].
Stereotactic body radiation therapy (SBRT) is a noninvasive cancer treatment, and has proven to be an effective and well-tolerated treatment in numerous studies for early stage LC in medically inoperable patients [1012]. However, severe ILD is considered a relative contraindication in the clinical guidelines for SBRT published by the Japanese Society for Therapeutic Radiation and Oncology, as a Japanese national survey of SBRT found that most patients with pulmonary grade 5 radiation pneumonitis (RP) had ILD [13]. High post-treatment mortality, even with mild ILD, has caused great difficulty in designing treatments for ILD-LC patients, and treatment results remain unsatisfactory [14].
In 1994, the National Institute of Radiological Sciences (NIRS) began exploring carbon-ion radiotherapy (CIRT) as a treatment for non-small cell lung cancer (NSCLC). Carbon-ion beams offer unique treatment advantages compared to other radiation modalities, including the delivery of a highly precise dose concentration to the target, with high linear energy transfer and relative biological effectiveness throughout the spread-out Bragg peak [15]. As reported previously, hypofractionated CIRT has produced excellent local control rates that are comparable to those of surgery or SBRT, with markedly low toxicities [1619].
In this study, we evaluated the toxicity and efficacy of CIRT for treating NSCLC in patients also presenting with ILD.

Methods

Study design and patient selection

We performed a retrospective evaluation of all patients with ILD-LC who were treated with CIRT at our hospital. Owing to the presense of ILD, all enrolled patients were ineligible for curative surgery and conventional radiotherapy.We diagnosed ILD was according to medical history, physical examination, respiratory function test, and evaluation of abnormalities compatible with bilateral lung fibrosis on chest computed tomography (CT) or high-resolution CT, such as peripheral reticular opacities. Biochemical tests for levels of lactate dehydrogenase, surfactant protein-D (SP-D), and serum Krebs von den Lungen-6 (KL-6) were also performed.
The treatment method and procedure were approved by the ethics committees of our institute, and written informed consent was obtained from all patients included in the study.

Lung cancer staging and interstitial lung disease severity

Initial workup included clinical and laboratory examinations, contrast-enhanced CT of the chest, contrast-enhanced magnetic resonance imaging (MRI) of the brain, and [11C]-acetate or [18F]-fluorodeoxyglucose (18F–FDG) positron emission tomography (PET)/CT scanning for detecting involved lymph nodes and distant metastases. The severity of ILD was evaluated according to the criteria of the Japanese Respiratory Society classifications [20].

Carbon-ion radiotherapy procedure

Carbon ion beams with 290, 350, and 400 MeV of nucleon energy were generated in the Heavy Ion Medical Accelerator in Chiba (HIMAC) synchrotron and delivered to the treatment room. The details of CIRT planning and delivery at our institution have been described previously [16, 18, 19, 21].
Between June 2004 and November 2014, CIRT was performed on 637 patients with primary NSCLC lesions at our institution; among them, 29 patients had ILD. Two patients were diagnosed with hilar lymph node metastasis. Three patients had suspected mediastinal lymph node metastasis on PET/CT, and 1 had suspected accessory nerve lymph node metastasis. We treated only the primary lesions of these patients, as Konishi et al. and Roberts et al. reported that inflammatory pulmonary lesions may show increased uptake of 18F–FDG [22, 23]. Additionally, 1 patient was diagnosed with an intrapulmonary metastatic lesion near their primary tumor. Both primary and metastatic lesions were treated in the same field.
For stage I LC patients and 4 patients with suspected lymph node metastases, the primary tumors were irradiated with carbon-ion beams at a fixed dose of 52.8 Gy (relative biological effectiveness [RBE]) (13.2 Gy[RBE]/fraction) for T1 (≤3 cm) tumors and 60.0 Gy (RBE) (15 Gy[RBE]/fraction) for T2 (>3 cm) tumors, delivered in 4 fractions over the course of 1 week. A single T4 patient was included in the T2 tumor group; this patient’s primary tumor and nearby intrapulmonary metastatic lesion were irradiated. After February 2012, primary tumors in stage I LC patients were irradiated in a single fraction at doses prescribed by the NIRS Lung Cancer Single Fraction Clinical Trial [19]. For single fraction delivery, tumors were normally irradiated from 4 ports consecutively. The HIMAC delivery system allowed for patients to be rotated a maximum of ±20 degrees, allowing for four different treatment angles between the horizontal and vertical particle beams.
In accordance with routine practice at our institute for stage I NSCLC, all CIRT plans utilized 4 coplanar and oblique beam fields at mutual angles of 40 or 50 degrees.
For two patients with stage II NSCLC who had hilar lymph node metastases, the primary tumor and involved lymph nodes were contoured as the gross tumor volume. The clinical target volume included the primary tumor with 10-mm margins in all directions. Prophylactic regional nodal irradiation that included targeting the ipsilateral hilar and mediastinal lymph nodes was chosen for one of the patients with a hilar lymph node metastasis. For the other patient, only the primary tumor and involved lymph node were irradiated. The prescribed dose (72 Gy [RBE]) was administered to the primary tumor, and a reduced dose was delivered to the CTV up to a total dose of 50 Gy (RBE) at the discretion of the treating physician. A fixed dose of 72 Gy (RBE) was delivered over a course of 16 daily fractions administered on four consecutive days per week and over four consecutive weeks.
The planning target volume (PTV) was enclosed by the 95% isodose line for conformal treatment with the prescribed dose. Dose constraints were strictly adhered to, regardless of potential target coverage compromise, as follows: spinal cord, 30 Gy (RBE); esophagus, 50 Gy (RBE); and mainstem bronchus, 60 Gy (RBE). Figure 1 shows a sample of the dose distribution for a patient wih stage I disease.

Follow-up

After the end of radiotherapy, regular follow-up examinations were performed every 3 months for the first 2 years and every 6 months thereafter. Each follow-up session included a physical evaluation, chest CT, brain MRI, respiratory function test, and laboratory tests at a minimum. Additional imaging investigations such as bone scanning and PET/CT were performed upon clinical suspicion of recurrence.

Radiation pneumonitis grading and the definition of acute exacerbation

The severity of RP was graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. As many patients had respiratory symptoms prior to CIRT, symptoms were graded before and after CIRT, and symptomatic grade change was evaluated. The occurrence of AE was defined according to the revised Japanese criteria for AE of IPF [20], which states that all of the following three conditions must be satisfied during the course of IPF within a single month: 1) worsening or development of dyspnea 2) new ground-glass opacities appear on high-resolution CT in addition to previous honeycomb lesions, new ground-glass abnornalities, and/or consolidation superimposed on a background reticular or honeycomb pattern on high-resolution CT 3) a greater than 10 mmHg reduction of partial pressure of oxygen in the arterial blood under similar conditions. The ruling out of alternative causes, such as infection, pneumothorax, cancer, pulmonary embolism or congestive heart failure is required. Due to the difficulty of distinguishing AE from RP, AE was confirmed when infiltrates were observed outside the radiation field.

Statistical analysis

All data are presented as median values with ranges. We used JMP statistical software (version 11.0) for all statistical analyses. To investigate the relationships between patients with or without IP grade progression, clinical characteristics and treatment-related factors were compared using the Mann-Whitney U test or Fisher’s exact test.
Overall survival was defined as the time elapsed from the start of CIRT to death or to last follow-up date (i.e., last hospital visit, phone call, or mailed communication). Patients lost to follow-up or who were alive at the end of the study were censored. The local control rate was calculated from the date of initial CIRT to the first local recurrence was first detected, or that of the patient’s last follow-up visit. The overall survival and local control rates were analyzed using Kaplan-Meier statistics. Cox proportional hazards analysis was conducted to identify prognostic factors. A p-value less than 0.05 was considered statistically significant. Any AEs occurring after radiotherapy were evaluated qualitatively on an individual basis due to their low numbers.

Results

Patient characteristics and the severity of interstitial lung disease

In total, 637 consecutive patients with NSCLC who underwent CIRT between June 2004 and November 2014 were investigated retrospectively. Of these, 29 patients with ILD were identified; their characteristics are listed in Table 1. Prior to CIRT, 11 grade 1 patients, 6 grade 2 patients, 8 grade 3 patients, and 4 grade 4 patients were identified according to the Modified Medical Research Council Dyspnea Scale [24]. Under the CTCAE v.3.0 criteria, there were 11 grade 1 patients, 14 grade 2 patients, 4 grade 3 patients, and no grade 4 or 5 patients. Four patients were using home oxygen therapy, 4 had a history of AE prior to treatment, and 4 had a prior autoimmune disease.
Table 1
Pretreatment patient characteristics
No. of patients
29
Follow-up period median (range)
26.8 (2.7–86.5)
Gender (male/female)
28/1
Age median (range)
73 (62–90)
Performance Status (ECOG) 0/1/2/3
15/13/2/0
Smoking history (pack years) median (range)
42 (0–210)
Severity of ILD (grade 1/2/3/4)
9/10/6/4
Dyspnea evaluation before CIRT
 
 No. of patients using home oxygen therapy
4
 mMRC scale (grade 0/1/2/3/4)
0/11/6/8/4
 equivalent RP grade CTCAE ver 3.0 (grade 1/2/3/4/5)
11/14/4/0/0
 %FVC median (range)a
82.3 (37.9–117.6)
 %DLco median (range)a
52.1 (15.5–235.5)
Tumor size
34 (17–63)
 T1a (≤2 cm)
2
 T1b (2-3 cm)
8
 T2a (3-5 cm)
14
 T2b (≥5 cm)
5
Tumor location
3000
 Upper lobe (including 2 tumors in middle lobe)
15
 Lower lobe
14
Nodal involvement (yes/no/suspected)
2/23/4
 Location of nodal involvement of 2 patients
#11 (left hilar lymph node)
Histology
 Adenocarcinoma
8
 Squamous cell carcinoma
10
 Unclassified non-small cell carcinoma
2
 Clinically diagnosed
9
Laboratory Data
 serum KL-6 (U/l) median (range)
1167 (456–2410)
 serum SP-D (ng/l) median (range)
157 (31–502)
The time of ILD diagnosis
 at the same time as lung cancer diagnosis
14
 unknown
1
 before diagnosis of lung cancer
14
Period from ILD to cancer diagnosis (median years) (range)
4 (2–13)
Episode of acute exacerbation before treatment (yes/no)
4/25
Auto-immune disease (yes/no)
4/25
*data are available only for 26 patients
Abbreviations: ECOG Eastern Cooperative Oncology Group, ILD interstitial lung disease, CIRT carbon ion radiotherapy, mMRC scale the modified Medical Research Council scale, FVC forced vital capacity, DLco diffusion capacity of the lung, KL-6 Krebs von den Lungen-6, SP-D surfactant protein D

Treatment characteristics

An evolving series of protocols were employed during the treatment period, the details of which are shown in Table 2. Treatment timeframes ranged between 1 day (46–50 Gy [RBE], single fraction; 13 patients), 4 days (52.8–60 Gy[RBE], 4 fractions; 14 patients), and 4 weeks (72 Gy[RBE], 16 fractions; 2 patients). The PTV ranged from 34.6 mL to 1319.8 mL (median: 145.1 mL).
Table 2
Treatment characteristics and dose volume analysis
Protocol
No. of pts.
 46.0Gy (RBE) /1fr/1 day
1
 48.0Gy (RBE)/1fr/1 day
4
 50.0Gy (RBE)/1fr/1 day
8
 52.8Gy (RBE)/4fr/4 days
7
 60.0Gy (RBE)/4fr/4 days
7
 72.0Gy (RBE)/16fr/4wks
2
PTV volume (ml), median (range)
85.3 (34.6–1319.8)
Dosimetric factors of the lung (%), median (range)
 V5 lung
10.5 (3.0–34.8)
 V10 lung
8.6 (2.6–32.8)
 V15 lung
7.1 (2.2–27.1)
 V20 lung
6.2 (2.0–18.0)
 V25 lung
4.6 (1.8–16.8)
 V30lung
4.0 (1.5–15.9)
 Mean Lung Dose
3.5 (1.0–12.2)
Abbreviations: RBE relative biological effectiveness, PTV planning target volume

Pre- and post-treatment radiation pneumonitis and radiation-induced AE

We detected RP of grades 1, 2, and 3 in 9, 12, and 8 patients, respectively (Table. 3). Five patients experienced RP grade progression. Four patients experienced a single RP grade increase, from 1 to 2 or 2 to 3, following treatment; 1 patient had a 2-degree increase, from 1 to 3. Two patients experienced radiation-induced AE.
Table 3
RP Grade and incidence of acute exacerbation
RP grade (CTCAE ver3.0)
 1
9 (31%)
 2
12 (41%)
 3
8 (28%)
RP grade progression after treatment
 0/1/2
24/4/1
Acute exacerbation
2 (7%)a
RP symptom onset time
 
 no symptom
15 (52%)
 0–3 month
9 (31%)
 3–6 month
5 (17%)
aThese patients are also included in RP grade 3 data
Abbreviations: CTCAE Common Terminology Criteria for Adverse Events, RP radiation pneumonitis

Clinical outcomes

The median follow-up period was 26.8 months (range, 2.7–86.5 months) for all patients. The overall survival rates at 3 and 5 years was 46.3 and 30.4% (57.2 and 42.4% for stage I disease), respectively (Fig. 2). Eighteen of 29 patients (62.1%) showed a survival of longer than 2 years. Eighteen patients had died at the time of this writing, 10 of LC progression, 2 of other cancers (1 pancreastic, and 1 myelodysplastic syndrome), and 6 of noncancerous causes (3 of bacterial pneumonia, 2 of hypoxia due to progression of ILD, and 1 of gastrointestinal hemorrhage). The deaths from hypoxia resulting from ILD occurred more than 40 months after undergoing CIRT in both patients. We observed eight local recurrences; the median time between CIRT and diagnosis of local recurrence was 17.2 months. The local control rates at 3 and 5 years were both 63.3% (72.2% for stage I disease only).

Acute exacerbation

Two patients were diagnosed with AE of their ILD post-CIRT. One was a 76-year-old man with stage IA LC, and the other an 80-year-old man with stage IB LC. They were diagnosed with AE by CT scanning following hospital admission due to worsening dyspnea, which revealed ground glass opacities outside the irradiated field. Both were treated with oxygen and steroid pulse therapy. The AE subsided in both patients, although the man with stage IA disease died of gastrointestinal hemorrhage 1 month following admission. The patient with stage IB disease was discharged, but died of bacterial pneumonitis 5 months after radiotherapy.

Radiation pneumonitis grade progression and related factors

Table 4 shows the relationships between the RP grade progression and pretreatment clinical factors as well as dosimetric factors in the 29 patients. The lung doses of V5 and V10 were significantly associated with the occurrence of RP grade progression (p = 0.026 and 0.033). Pre-treatment serum SP-D was also found to correlate with grade progression, and was significantly lower in the grade-progressing patient population (p = 0.036).
Table 4
Clinical and dosimetric factors associated with symptoms after CIRT
 
no grade change (n = 24)
grade progression (n = 5)
p-value
Clinical factors
 Age (yr), median (range)
72.0 (62–90)
76.0 (71–86)
0.224
 Performance Status (0/1/2)
13/9/2
1/4/0
0.330
 Severity of ILD (JRS) (1/2/3/4)
9/7/4/4
0/3/2/0
0.434
 mMRC scale (1/2/3/4/5)
0/9/6/5/4
0/2/0/3/0
0.952
 Tumor location (U/L)
11/13
3/2
1.000
 Tumor size (mm), median (range)
34.0 (17–58)
31.0 (22–63)
0.544
 serum KL-6, median (range)
880.5 (325–2410)
544.0 (466–1199)
0.260
 serum SP-D, median (range)
152.0 (60–502)
105.0 (31–140)
0.036
Respiratory function, median (range)
 %VC
90.7 (43.5–130.4)
86.7 (64.9–107.3)
0745
 %FVC
81.8 (37.9–117.6)
82.7 (52.8–98.7)
0.820
 FEV1.0 (L)
2.0 (1.13–2.92)
2.0 (1.47–2.96)
1.000
 FEV1.0/VC (%)
80.7 (54.0–91.2)
78.6 (72.7–99.7)
0.696
 %DLco
50.7 (15.5–92.2)
70.7 (39–235.5)
0.474
 Not evaluated
3
0
 
Dose-volume metrics, median (range)
 PTV (mL)
82.9 (34.6–345.9)
88.1 (52.3–1319.8)
0.507
 Total dose (Gy[RBE]),
52.8 (46–72)
50.0 (50–72)
0.5745
Dosimetric factors of the lung (%), median (range)
 V5
8.7 (3.0–20.6)
14.2 (10.9–34.8)
0.026
 V10
7.6 (2.6–18.3)
11.9 (8.4–32.8)
0.033
 V15
5.6 (2.2–13.6)
8.0 (7.1–27.1)
0.074
 V20
5.0 (3.0–20.6)
7.3 (6.2–18.0)
0.069
 V25
4.2 (1.8–11.0)
5.4 (3.3–16.8)
0.237
 V30
3.7 (1.5–9.0)
4.9 (2.8–15.9)
0.286
 V35
3.4 (1.4–8.5)
4.4 (2.5–5.0)
0.260
 V40
3.1 (1.3–8.0)
4.0 (2.2–14.0)
0.260
Mean Lung Dose (Gy[RBE])
2.8 (1.0–6.4)
3.8 (3.0–12.2)
0.075
Abbreviations: CIRT carbon ion radiotherapy, ILD interstitial lung disease, JRS Japanese Respiratory Society, mMRC scale the modified Medical Research Council scale, KL-6 Krebs von den Lungen-6, SP-D surfactant protein D, VC vital capacity, FVC forced vital capacity, FEV1.0 Forced Expiratory Volume in one second, DLco diffusion capacity of the lung, PTV planning target volume, RBE relative biological effectiveness

Discussion

In this study, we aimed to evaluate the CIRT toxicity profile for LC patients with preexisting ILD-LC, for whom conventional radiation therapy such as SBRT is contraindicated. We evaluated 29 patients who were ineligible for surgery due to a previous diagnosis of ILD by examining the degree of RP in their lungs following treatment, as well as the degree of symptomatic change, and any AEs due to treatment.
SBRT is the typical first-line radiological intervention for early stage non-resectable LC. However, in the setting of ILD, the high risk of RP and AE limits radiotherapy to a small proportion of patients. In Yamashita et al.’s evaluation of SBRT in 117 ILD-LC patients, 9 cases of Grades 4–5 RP were noted and investigated; pretreatment blood KL-6 and SP-D levels, as well as the presence of an interstitial pneumonitis shadow, were found to be predictive of RP [25].
More recently, Ueki et al. evaluated 191 patients, 12 with mild and eight with severe cases of ILD. They found that the presence of ILD and the volume of the irradiated lung were associated with the development of grade 2 or higher RP. Furthermore, survival in the ILD group was poor compared to that in the base group [26]. Yamaguchi et al. further evaluated a group of 109 patients treated with SBRT at their institution. 16 were found to have subclinical ILD on CT and treated among these patients. Of 13 patients with post-treatment grades 2–5 RP, three were in the subclinical ILD group. Although subclinical ILD did not correlate with grades 2–5 RP in their study, the rate of extensive RP was notably high in these patients. Moreover, they reported that 2 patients with subclinical ILD developed Grade 4–5 RP [14].
The majority of the 29 patients in this trial presented with respiratory symptoms and clear interstitial opacities prior to treatment. Typically, this population of patients is offered best supportive care with no additional treatment. To our knowledge no other radiotherapy study targeted to this specific population has been performed.
The CTCAE were used to grade post-treatment pneumonitis. However, 14 of the 29 patients in our study (48%) presented with pretreatment grade 2-equivalent symptoms, while 4 (14%) presented with Grade 3 equivalent symptoms. As such, we postulate that the direct grading of symptoms following radiotherapy accuracy reflect post-treatment change. We evaluated the respiratory symptom grade progression over the course of treatment, and observed progression in 5 cases. Furthermore, ILD-related AE was noted in 2 patients; both grade 3 events. Despite the extremely high risk associated with these patients, the relative lack of serious adverse events (higher than grade 3) was noteworthy.
Although predicting the exact prognosis of ILD is difficult owing to the varying classifications involved, ILD-LC generally has a poorer prognosis in comparison to uncomplicated LC [4, 27]. In examining IPF specifically, Vancheri et al. and Ley et al. noted median survival times of between 2 and 3 years for IPF-LC patients [28, 29]. Prognosis times for ILD-LC patietns remain difficult to predict, especially for those diagnosed with ILD prior to developing LC and who therefore received prior treatment. In this study, approximately half of the patients (14) were discovered to have ILD at the time of their cancer diagnosis, while the remainder received an average of 4 years of treatment prior to their LC diagnosis.
Compared to surgical patients, the average age was high in our cohort, while forced vital capacity and diffusing capacity for carbon monoxide were low. Furthermore, the patients had clear interstitial changes on imaging that disqualified them from consideration for SBRT. Compared to patients who underwent SBRT, the rate of AEs in our patients was low, while comparable overall survival rates were noted. These data are shown in the Table 5 [59, 14, 30]. On the other hand, the local control rates in our study were lower than those among SBRT patients [14]. A possible explanation is that a higher percentage of our patients had T2 tumors (65.5%). However, the local control rates in patients without ILD in our study were comparable to those in patients who underwent SBRT ([1619]), and patients with and without ILD underwent the same treatment protocol. Hence, further explanations remain elusive.
Table 5
Representative reported results of treatment for NSCLC with ILD
Author
year
treatment
disease
No of all pts
combined disease
No of pts. with ILD (%)
Age
median follow-up period (month)
AE (%)
Mortality after AE (%)
3 yr. OS (%)
5 yr. OS (%)
%FVC (or %VC)
%DLco
Chiyo
2003
surgery
NSCLC
931
ILD
36 (3.9)
65.5
43.8
9 (25)
1 (11.1)
41.5
35.6
84.9
Mizuno
2012
surgery
NSCLC
1444
IPF
62 (4.3)
71.6
7 (13.5)
6 (85.7)
%VC 95.3
51.1
Voltolini
2013
surgery
NSCLC
775
ILD
37 (4.8)
69.3
26
5 (13.5)
3 (60)
52
91.4
59.7
Sato
2014
surgery
NSCLC
41,742
ILD
1763 (4.2)
71
164 (9.3)
72 (43.9)
%VC < 80% 263
2015
40
%VC > 80% 1478
Omori
2015
surgery
NSCLC
678
IPF
46
70.9
34.3
4 (8.7)
3 (75)
50.9
22.1
89.8
70.6
Non-IPF
57
70.9
1 (1.8)
0
71.5
53.2
98.5
71.7
Yamaguchi
2013
SBRT
NSCLC, MLT
109
subclinical ILD
16 (14.7)
78
17.1
2a (12.5)
1b (50)
48
present
2015
CIRT
NSCLC
637
ILD
29 (4.6)
73
22.8
2 (6.9)
0
46.3
30.4
82.3
52.1
stage I NSCLC
ILD
22
73
22.6
2 (9.1%)
0
57.2
42.1
81.8
55.1
aGrade4–5 RP, bGrade5 RP
Abbreviations: NSCLC non-small cell lung cancer, ILD interstitial lung disease, AE acute exacerbation, IPF interstitial pulmonary fibrosis, OS overall survival rate, FVC forced vital capacity, VC vital capacity, DLco diffusion capacity of the lung, MLT metastatic lung tumor, CIRT carbon ion radiotherapy, RP radiation pneumotinis
In previous studies of LC treated with SBRT, PTV, V5,V13, V20, V25, Vprescription and mean lung dose were among the factors that showed a correlation with the severity of RP post-treatment [3134]. In the 5 patients in our study who experienced disease progression, V5 and V10 lung doses were significantly associated with RP grade progression. However, the lung doses in these 5 patients are as low as the doses reported in the SBRT trials [13, 14, 33, 34], as heavy-ion therapy allows for improved minimization of non-target doses. Our results suggested that small differences in lung dose may significantly affect the severity of RP in symptomatic ILD patients.
With respect to the 2 cases that exhibited AE, we evaluated respiratory function tests, blood tests, dosimetric factors, and other factors to determine whether they predicted exacerbation. However, no such associations were found.
At PET pretreatment staging of the patients’ cancers, highly integrated mediastinal lymph nodes were noted in 3 cases, and an accessory nerve lymph node metastasis was noted in 1 case. Among these cases, a lymph node with a minor axis greater than 10 mm was found in only 1 patient. Roberts et al. previously reported that, among the 7 cases of mediastinal lymph node false positives of 100 examined on PET, 4 were likely caused by inflammation in the lung parenchyma [23]. Additionally, Konishi and colleagues examined 306 mediastinal lymph nodes in 54 patients and found 7 false positives, 2 of which were caused by interstitial pneumonia [22]. Considering these reports, the 4 cases of pretreatment lymph node metastases noted on PET/CT in our ILD-LC patients may have included false positives; hence, only the primary tumors were treated. Of the 4 potential metastasis cases, none were found to have lymph node metastasis after CIRT.
As this study was retrospective, there remains the possibility that selection bias may have impacted the results, as all patients included were ineligible for surgery and SBRT because of the clear risk posed by their ILD.

Conclusions

In this study, most of patients presented with respiratory symptoms and clear interstitial opacities prior to treatment; this population had had few available treatment options outside of supportive care. Considering these unfavorable conditions, we demonstrated the efficacy and relative safety of the use of CIRT in LC patients with ILD. Dose-volume histogram analysis suggested the importance of minimizing the low-dose region, as the lung doses V5 and V10 lung doses were significantly associated with RP grade progression. As relatively few patients were evaluated in this study, a larger trial with long-term follow-up is warranted to verify these results.

Acknowledgements

This work was supported by the Research Project with Heavy Ions at NIRS-HIMAC. We are grateful to Dr. Kazuhisa Takahashi (Department of Respiratory Medicine, Juntendo University Graduate School of Medicine) and the Working Group for Lung Cancer at the NIRS.

Funding

This work did not receive any specific funding.

Availability of data and materials

The datasets used and /or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

All study participants provided informed consent, and we obtained general consent to the research in written form from the participant. The treatment method and procedure were approved by the ethics committees of our institution.

Consent for publication

We obtained consent for publication in written form from the patient described in Fig. 1.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2017

Radiation Oncology 1/2017 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise